๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Immune Checkpoint Therapy

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation NCT06843551Phase 21 site๐Ÿ“ Miami Benjamin Spieler ยท Tests: Stereotactic Body Radiation Therapy, Botensilimab, Balstilimab Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites๐Ÿ“ Nanjing๐Ÿ“ Nanjing Zhongda Hospital Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma NCT07704918NA1 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolโ€ฆ Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779NA1 site๐Ÿ“ Ljubljana Institute of Oncology Ljubljana ยท Tests: Pembrolizumab, Nivolumab, Ipilimumab Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Dalpiciclib Isetionate Tablets, Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor) Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma NCT07595770Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: โ€ข Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Bright Light Therapy Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors NCT05141474EARLY Phase 11 site๐Ÿ“ Barcelona Vall d'Hebron Institute of Oncology ยท Tests: NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen, Interleukin-2 Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer NCT03942328Phase 1, Phase 21 site๐Ÿ“ Rochester Mayo Clinic ยท Tests: Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer NCT06613165n/a1 site๐Ÿ“ Xi'an Xijing Hospital The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer NCT07257653Phase 21 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: Cetuximab ฮฒ๏ผ›Fruquintinib๏ผ›, Cetuximab ฮฒ๏ผ›Fruquintinib๏ผ›anti-PD1 antibody๏ผ›, Cetuximab ฮฒ๏ผ›Fruquintinib๏ผ›anti-PD1/CTLA4 antibody TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. NCT06669377n/a1 site๐Ÿ“ Nanjing Zhongda Hospital Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients NCT07130981n/a1 site๐Ÿ“ Ankara Hacettepe University Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response NCT06239727Phase 326 sites๐Ÿ“ Fuzhou๐Ÿ“ Xiamen๐Ÿ“ Dongguan Sun Yat-sen University ยท Tests: PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2), Reduced-dose Intensity-modulated radiotherapy, Conventional-โ€ฆ Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment NCT05813418NA1 site๐Ÿ“ Amiens Centre Hospitalier Universitaire, Amiens ยท Tests: blood retriewal STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy NCT06337097NA1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Troponin surveillance, Standard of care A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies NCT03847649Phase 211 sites๐Ÿ“ Edmonton๐Ÿ“ Kelowna๐Ÿ“ Vancouver Canadian Cancer Trials Group ยท Tests: Durvalumab, Prednisone, Prednisone, Tremelimumab Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623Phase 1, Phase 2126 sites๐Ÿ“ Phoenix๐Ÿ“ Fullerton๐Ÿ“ Oxnard AbbVie ยท Tests: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma NCT07863258n/a5 sites๐Ÿ“ Anderlecht๐Ÿ“ Bonheiden๐Ÿ“ Bruges Universitaire Ziekenhuizen KU Leuven Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer NCT06765616Phase 21 site๐Ÿ“ Jinan Feng Tian ยท Tests: Adebrelimab Injection combined with radiotherapy and chemotherapy Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893Phase 1, Phase 211 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Denver Phanes Therapeutics ยท Tests: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDAยฎ (pembrolizumab) Combination of TATE and PD-1 Inhibitor in Liver Cancer NCT03259867Phase 23 sites๐Ÿ“ Orange๐Ÿ“ Oklahoma City๐Ÿ“ Milwaukee Teclison Ltd. ยท Tests: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT06790602Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: Cemiplimab Plus Gemcitabine Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer NCT07320586Phase 21 site๐Ÿ“ Jinan Shandong Tumor Hospital ยท Tests: Camrelizumab, Nab paclitaxel The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study NCT07141056n/a5 sites๐Ÿ“ Zhanjiang๐Ÿ“ Guilin๐Ÿ“ Guilin Guilin Medical University, China ยท Tests: Psychological Stress Status, Psychological Stress Status, Psychological stress status A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer NCT07603856Phase 21 site๐Ÿ“ Chicago University of Chicago ยท Tests: Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Inveโ€ฆ IMMUNO-FIT Observational Study NCT07354971n/a1 site๐Ÿ“ Southampton University Hospital Southampton NHS Foundation Trust ยท Tests: Observational Study - No Study Intervention QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer NCT06917092Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: QL1706 combined with chemotherapy ยฑ Bevacizumab Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904Phase 382 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Los Angeles Iovance Biotherapeutics, Inc. ยท Tests: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients NCT05973344n/a1 site๐Ÿ“ Brest University Hospital, Brest
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy